New approaches to fight mycobacterial infections and drug resistance
Chemical biology studies of MmpL3 inhibition and resistance in mycobacteria
This research explores new ways to stop serious bacterial infections, like tuberculosis, by targeting a key protein in the bacteria and preventing drug resistance.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Michigan State University NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-11112316 on NIH RePORTER |
What this research studies
This project focuses on a protein called MmpL3, which is vital for mycobacteria, the germs that cause diseases like tuberculosis, to survive. We are working to find and understand new compounds that can block MmpL3, effectively stopping the bacteria from growing. Our goal is to develop powerful new medicines that can kill these bacteria, even those that have become resistant to existing drugs. We are also looking into how these new compounds might work together with current tuberculosis treatments to improve patient outcomes.
Who could benefit from this research
Good fit: This foundational research is not directly recruiting patients but aims to benefit individuals suffering from mycobacterial infections, such as tuberculosis or M. abscessus infections.
Not a fit: Patients without mycobacterial infections would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to the development of new, more effective drugs to treat serious mycobacterial infections, including drug-resistant tuberculosis.
How similar studies have performed: MmpL3 is a known therapeutic target, and previous studies have shown that inhibiting it can stop mycobacterial growth, supporting the approach of this project.
Where this research is happening
East Lansing, United States
- Michigan State University — East Lansing, United States (Active)
Researchers
- Principal investigator: Abramovitch, Robert B — Michigan State University
- Study coordinator: Abramovitch, Robert B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.